Harnessing Lipids and Synthetic Biology to Extend Healthspan and Longevity

At Lucina Biotherapeutics, we have harnessed the power of synthetic biology to extend healthspan and promote longevity. Aging is the leading risk factor for numerous disorders that impair quality of life. Research has shown that the age-related decline in VLC-PUFA tissue levels, driven by epigenetic downregulation of the ELOVL2 gene, accelerates aging processes and contributes to dysfunction across multiple systems.

Our innovative yeast platform targets this decline, restoring VLC-PUFA concentrations in tissues to rejuvenate cells and reverse aging-related dysfunction. By addressing this root cause of aging, we aim to transform  health and longevity.

Endogenous biosynthesis of very long-chain polyunsaturated fatty acids (VLC-PUFAs) produces a variety of species differing in carbon chain length and degree of unsaturation. Each VLC-PUFA species plays a unique biological role, and evidence suggests that the complete spectrum is essential for optimal cellular function. However, studies have shown that VLC-PUFA levels decline with age, contributing to cellular dysfunction and age-related disorders. Restoring the full range of VLC-PUFAs is likely critical for effective cellular rejuvenation.

Lucina Biotherapeutics has addressed this challenge by engineering a proprietary strain of baker’s yeast to produce the natural spectrum of VLC-PUFAs. These VLC-PUFAs are readily absorbed and efficiently targeted to key tissues following oral administration. Moreover, baker’s yeast is widely recognized as safe for oral consumption, making it an ideal delivery platform. Our yeast-based solution offers a sustainable, effective approach to restoring VLC-PUFA levels and reversing aging-related cellular dysfunction.